Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS

https://doi.org/10.20996/1819-6446-2012-8-6-738-745

Full Text:

Abstract

Aim. To evaluate drug therapy received by patients who had survived acute myocardial infarction (AMI) in the framework of the AMI register (the “LIS” study) and estimate this therapy influence on long-term outcomes of the disease. Material and methods. The total of 961 patients of 1133 enrolled in the “LIS” study , were discharged from hospital. 191 patients had died during follow-up. 632 patients (who had survived and consented to visit out-patient clinic) underwent repeated examination (median of follow-up 1.6 [1.0; 2.4] years). Data about treatment before and during AMI were received from patient’s charts; data about treatment after AMI were obtained from out-patient medical records. Results. Before reference AMI only a small number of the patients received the main drug groups (antiplatelet agents, β-blockers, ACE inhibitors, statins), at that ACE inhibitors were prescribed more often than the others. Use of β-blockers and ACE inhibitors before reference AMI significantly improved long-term life prognosis [relative risk (RR) 0.70 and 0.66, respectively]. Rate of the main drug groups prescribed in hospital was rather high with the exception of thrombolytics (less than 10%). Thrombolytics, β-blockers and antiplatelet agents prescribed in hospital significantly improved long-term life prognosis of patients (RR 0.42, 0.65 and 0.58 respectively). At the second visit (according to data of out-patient medical records) rate of antiplatelet agents, ACE inhibitors, β-blockers and statins prescription exceeded 60%. Conclusion. Very low prevalence of adequate drug therapy preceding AMI determines high mortality rate among survived acute stage of myocardial infarction patients in long-term period.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine I.M. Sechenov First Moscow State Medial University
Russian Federation

PhD, MD, Head of Department of Preventive Pharmacotherapy, State Research Center for Preventive Medicine; Professor of Chair of Evidence-based Medicine, I.M. Setchenov First Moscow State Medical University



M. L. Gynzburg
Lyubertsy Regional Hospital №2
Russian Federation
PhD, MD, Head of Cardiology Department


N. P. Kutishenko
State Research Center for Preventive Medicine I.M. Sechenov First Moscow State Medial University
Russian Federation

PhD, MD, Head of Laboratory of Preventive Pharmacotherapy, Department of Preventive Pharmacotherapy, State Research Center for Preventive Medicine; Professor of Chair of Evidence-based Medicine, I.M. Setchenov First Moscow State Medical University



A. D. Deev
State Research Center for Preventive Medicine
Russian Federation

PhD, Head of Laboratory of Biostatistics, Department of Preventive Pharmacotherapy



V. P. Smirnov
Lyubertsy Regional Hospital №2
Russian Federation
PhD, MD, Head of L yubertsy Regional Hospital №2


L. U. Drozdova
State Research Center for Preventive Medicine
Russian Federation

PhD, MD, Researcher of Department of Preventive Pharmacotherapy



E. V. Daniels
Lyubertsy Regional Hospital №2
Russian Federation
MD, Doctor of Cardiology Department


A. V. Fokina
Lyubertsy Regional Hospital №2
Russian Federation
MD, Doctor of Cardiology Department


References

1. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316(7141):1337–1343.

2. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247(12):1707–1714.

3. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004;43(12):2200–2206.

4. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670–1676.

5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711–1718.

6. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13(1):28–32.

7. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980– 2000. N Engl J Med 2007;356(23):2388–2398.

8. Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003;21(10):1831–1840.

9. Kobalava Zh.D., Kotovskaya Yu.V., Sklizkova L.A., Moiseev V.S. Treatment and screening of elderly patients with hypertension: Perceptions of physicians and actual practice (according to the Russian scientific-practical program ARGUS) Arterial'naya Gipertenziya 2002;8(5):165–168. Russian (Кобалава Ж.Д., Котовская Ю.В., Склизкова Л.А., Моисеев В.С. Лечение и обследование пожилых больных с артериальной гипертонией: представления врачей и реальная практика (по данным Российской научно-практической программы АРГУС). Артериальная Гипертензия 2002;8(5):165–168).

10. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–1243.

11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121–137.

12. Larsen J, Andersen M, Bjerrum L, et al. Insufficient use of lipid-lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction. J Cardiovasc Risk 2003;10(1):61–64.

13. Alpert JS. Are data from clinical registries of any value? Eur Heart J 2000;21(17):1399–1401.

14. Dyke CK, Calif RM. National and regional registries: what good are they? Eur Heart J 2000;21(17):1401– 1403.

15. Fox KA. Registries and surveys in acute coronary syndrome. Eur Heart J 2006;27(19):2260–2262.

16. Krumholz HM, Chen J, Chen YT, et al. Predicting one-year mortality among elderly survivors of hos-pitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 2001;38(2):453–459.

17. Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010;74(3):503– 509.

18. Martsevich S.Yu., Ginzburg M.L., Kutishenko N.P., et al. The LIS study (Lubertsy mortality study of patients with acute myocardial infarction): a portrait of the patient. Kardiovaskularnaya Terapiya i Profilaktika 2011;10(6):89–93.Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и соавт. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда): портрет заболевшего. Кардиоваскуларная Терапия и Профилактика 2011;10(6):89–93.

19. Martsevich S.Yu., Ginzburg M.L., Kutishenko N.P., et al. Lubertsy study on mortality in patients with acute myocardial infarction. The first results of the study «LIS». Klinitsist 2011;2:24–27. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и соавт. Люберецкое исследование по изучению смертности больных, перенесших острый инфаркт миокарда. Первые результаты исследования «ЛИС». Клиницист 2011;2:24–27).

20. Martsevich S.Yu., Ginzburg M.L., Kutishenko N.P., et al. Lubertsy mortality study of patients with acute myocardial infarction (LIS): analysis of anamnestic factors determining death in the hospital. Kardiovaskularnaya Terapiya i Profilaktika 2012; 11(1), 45-48. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и др. Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда (ЛИС): анализ анамнестических факторов, определяющих смерть в стационаре. Кардиоваскуларная Терапия и Профилактика 2012; 11(1): 45-48).

21. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001;357(9254):455–462.

22. Tuomilehto J, Wikstrand J, Olsson G, et al. Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study. Hypertension 1989;13(6 Pt 2):773–780.

23. Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998;19 Suppl J:J52–55.


For citation:


Martsevich S.Yu., Gynzburg M.L., Kutishenko N.P., Deev A.D., Smirnov V.P., Drozdova L.U., Daniels E.V., Fokina A.V. THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS. Rational Pharmacotherapy in Cardiology. 2012;8(6):738-745. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-6-738-745

Views: 348


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)